AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

Nov 21, 2017

Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition, Highlighting AbbVie's Commitment to Helping Blood Cancer Patients

NORTH CHICAGO, Ill., Nov. 21, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced that the American Society of Hematology (ASH) has accepted data from the Phase 3 MURANO study evaluating venetoclax tablets in combination with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL), as an oral, late-breaking presentation during the upcoming 59th ASH Annual Meeting & Exposition, December 9-12, in Atlanta, GA. The abstract is one of six late-breaking abstracts accepted for presentation at the meeting.

Nov 15, 2017

AbbVie to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference

NORTH CHICAGO, Ill., Nov. 15, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference on Wednesday, November 29, 2017. Bill Chase, executive vice president and chief financial officer, will present at 7 a.m. Central time.

Nov 03, 2017

AbbVie to Present at the Jefferies 2017 London Healthcare Conference

NORTH CHICAGO, Ill., Nov. 3, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Jefferies 2017 London Healthcare Conference on Thursday, Nov. 16, 2017. Bill Chase, executive vice president and chief financial officer, will present at 3:20 a.m. Central time.

Nov 01, 2017

AbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain

NORTH CHICAGO, Ill., Nov. 1, 2017 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced detailed results from two replicate Phase 3 extension studies evaluating the long-term efficacy and safety of elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) antagonist, being evaluated for the management of endometriosis with associated pain. In the extension studies, elagolix demonstrated sustained reduction in average monthly menstrual pelvic pain and non-menstrual pelvic pain in women through the 12-month treatment period. The safety and tolerability of elagolix was consistent with the anticipated effects of reduced estradiol levels and no new safety concerns were identified with elagolix use for the 12-month treatment period1. These results, and other additional abstracts, were presented at the American Society for Reproductive Medicine Scientific Congress & Expo (ASRM) in San Antonio.

Oct 27, 2017

AbbVie Reports Third-Quarter 2017 Financial Results

NORTH CHICAGO, Ill., Oct. 27, 2017 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2017.

Oct 27, 2017

AbbVie Increases Quarterly Dividend by 11 Percent

NORTH CHICAGO, Ill., Oct. 27, 2017 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) increased the company's quarterly cash dividend by 11 percent from $0.64 per share to $0.71 per share. 

Oct 27, 2017

AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain

NORTH CHICAGO, Ill., Oct. 27, 2017 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) antagonist, being investigated for the management of endometriosis with associated pain.  The FDA grants priority review to medicines that it determines have potential to provide significant improvements in the safety and effectiveness of the treatment of a serious disease1.  AbbVie expects the Prescription Drug User Fee Act (PDUFA) date for the FDA to complete its review will be in Q2 2018.

Oct 26, 2017

Risankizumab Meets All Co-Primary and Ranked Secondary Endpoints, Achieving Significantly Greater Efficacy Versus Standard Biologic Therapies in Three Pivotal Phase 3 Psoriasis Studies

NORTH CHICAGO, Ill., Oct. 26, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced positive top-line results from three pivotal Phase 3 clinical trials evaluating risankizumab, an investigational interleukin-23 (IL-23) inhibitor, compared to ustekinumab and adalimumab for the treatment of patients with moderate to severe chronic plaque psoriasis.1,2,3 Results showed that after 16 weeks of treatment, risankizumab (150 mg) met the co-primary endpoints of at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) and a static Physician Global Assessment (sPGA) score of clear or almost clear (sPGA 0/1) across all three studies versus placebo or adalimumab (based on trial design).1,2,3 Risankizumab is not approved by regulatory authorities and its safety and efficacy have not been established.

Oct 24, 2017

AbbVie to Showcase Robust Immunology Portfolio with New and Late-Breaking Data at the 2017 ACR/ARHP Annual Meeting

NORTH CHICAGO, Ill., Oct. 24, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced that data from 38 abstracts of HUMIRA® (adalimumab) and the company's portfolio of investigational immunology medicines will be presented at the 2017 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting, November 3-8, in San Diego.

Oct 24, 2017

Alector and AbbVie Announce Collaboration to Advance a Novel Class of Immune Therapies for Patients with Alzheimer's Disease

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Oct. 24, 2017 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global biopharmaceutical company, and Alector, a privately owned biotechnology company, today announced a global strategic collaboration to develop and commercialize medicines to treat Alzheimer's disease and other neurodegenerative disorders.